PRCRP Priorities for Fiscal Year 2022
In fiscal year 2022 the Peer Reviewed Cancer Research Program (PRCRP) of the Congressionally Directed Medical Research Programs (CDMRP) will provide funds for research into cancers…
Entries by Ayal Ronen
CDMRP Funding Opportunities 2022
CDMRP announced research funding opportunities for fiscal year 2022. CDMRP aim to fund high-risk, high-gain, high-impact projects which other funding agencies may overlook and thus to fill research gaps in critical areas. The FreeMind Group hosted a webinar about these new opportunities. Get the recording, slides, and critical forms here.
ALS Research Funding Opportunities from CDMRP in 2022
The Congressionally Directed Medical Research Programs (CDMRP) have announced their research funding opportunities for fiscal year 2022. Here’s an overview of the ALS funding opportunities. Learn more about these awards and others in our upcoming webinar, Wednesday, March 30, 2022, 1 PM (Eastern).
Breast Cancer Research Funding Opportunities from CDMRP in 2022
The Congressionally Directed Medical Research Programs (CDMRP) have announced their research funding opportunities for fiscal year 2022. Here’s an overview of the breast cancer research funding opportunities. Learn more about these awards and others in our upcoming webinar, Wednesday, March 30, 2022, 1 PM (Eastern).
BioTrinity, April 26-27, 2022 (London)
BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry.
The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.
Longevity Leaders World Congress, April 26-27, 2022 (London)
The Longevity Leaders World Congress brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies and commercialisation to target age-related diseases.
ARPA-H: What R&D will be funded by the “DARPA for Health”?
President Biden called on Congress to fund the creation of a new agency, a DARPA for Health. Some breakthrough ideas don’t receive sufficient attention because they are too high-risk, high-cost, or long-term, because they don’t fit well into academia or the commercial sector, or because they require complex collaborations. The Advanced Research Projects Agency for Health (ARPA-H) aims to support promising opportunities which concern health but which fall in that gap. ARPA-H will not have intramural labs. It will facilitate research directed at solving practical problems. To date, the kinds of non-dilutive funding opportunities which will be available through ARPA-H (grants, contracts, etc.) have not been defined, but we can make intelligent guesses.
How will Congress’ $1.5-Trillion Allocations Bill Affect Life Science R&D?
Spending bill ends funding for Biden’s COVID-19 programs, including some R&D, but does provide more funding for biomedical research: $45 billion for NIH, including $1 billion for Advanced Research Projects Agency for Health (ARPA-H), and $8.5 billion for the CDC.
Cell & Gene Meeting on the Med, April 20–22 & 26-27, 2022 (Hybrid: Barcelona & Online)
Premier conference for ATMP community in Europe and beyond